Author(s): A. S. Sathya Narayanan, K. S. Lakshmi, Raju Kamaraj

Email(s): sathyaas96@gmail.com

DOI: 10.5958/0974-360X.2020.00323.6   

Address: A. S. Sathya Narayanan*, Dr. K. S. Lakshmi, Raju Kamaraj
Department of Pharmaceutical Regulatory Affairs, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Kanchipuram, Tamil Nadu, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 4,     Year - 2020


ABSTRACT:
This review article mainly focuses on Eudravigilance (EV) the pillar for pharmacovigilance activities in the European Economic Area (EEA) which launched new operational plan for development of operational activity with anticipated timelines and also focuses on the Good Pharmacovigilance Practices (GVP) deals with analysis of safety data from uninhibited reporting systems with proven value for detection of risks of marketed medicines and with more modules of effected guidelines. EV system describes key activities and developments that will impact on or relate to itself and its stakeholders during the next 3 years from 2018 to 2020. The main aim is to ensure sustainability of EV and associated activities in support of the EU pharmacovigilance activities and protection of public health. The operational plan will be updated regularly as regards timelines and new activities/developments. In addition system interaction with the stakeholders as a part of training and communication engagement are covered to ensure that a platform for learning, cooperation and alignment throughout the evolution and operation of EV. GVP covers maintenance of risk management activities and to increase the beneficial effects of drug in population and maintenance of good reporting practices to avoid adverse reactions and the guidelines are based on population or product specific considerations and major pharmacovigilance process.


Cite this article:
A. S. Sathya Narayanan, K. S. Lakshmi, Raju Kamaraj. An Overview on Good Pharmacovigilance Practices and New Operational Plan Milestones of Eudravigilance in European Union. Research J. Pharm. and Tech. 2020; 13(4):1793-1798. doi: 10.5958/0974-360X.2020.00323.6

Cite(Electronic):
A. S. Sathya Narayanan, K. S. Lakshmi, Raju Kamaraj. An Overview on Good Pharmacovigilance Practices and New Operational Plan Milestones of Eudravigilance in European Union. Research J. Pharm. and Tech. 2020; 13(4):1793-1798. doi: 10.5958/0974-360X.2020.00323.6   Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-4-33


REFERENCE:
1.    Arun Sharma, S Amarnath, S Jaikumar, S. Basalingappa, S. Ramaswamy, M. Thulasimani. Assessment of Knowledge about Pharmacovigilance among Medical Students in Puducherry. Research J. Pharm. and Tech. 7(4): April, 2014; Page 447-449.
2.    Adamu Yau, Nordin Bin Simbak, Mainul Haque. Pharmacogenovigilance: A Potential Tool in Pharmacovigilance. Research J. Pharm. and Tech. 7(12): Dec. 2014; Page 1476-1482.
3.    https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance
4.    https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-training-support
5.    https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-auditable-requirement-project-eudravigilance-training-plan-version-5_en.pdf
6.    https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices#final-gvp-modules-section
7.    Eudra Vigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection Drug Safety, 2018, Volume 41, Number 7, Page 665
8.    Rodrigo Postigo, Sabine Brosch, Jim Slattery
9.    https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance-overview
10.    https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/pharmacovigilance-regulatory-procedural-guidance
11.    https://www.ema.europa.eu/en/documents/other/eudravigilance-operational-plan-milestones-2018-2020_en.pdf
12.    Avinash Khairnar, P.R. Gade. Interventional Improvement in Hospital Based Intensive Monitoring of Adverse Event. Research J. Pharm. and Tech. 4(9): Sept. 2011; Page 1443-1448.
13.    Sornalakshmi. K, Vadivu. G, Sujatha G, Hemavathi. D. A Survey on using Social Media Data Analytics for Pharmacovigilance. Research J. Pharm. and Tech 2017; 10(10):3474-3478.
14.    Bhavana B. Bhat, Udupa N, Sreedhar D. Knowledge and attitude of Ayurvedic Physicians towards Adverse drug reactions and reporting methods in Udupi region. Research J. Pharm. and Tech. 2018; 11(1): 117-120
15.    S. Janani, K. Manikandan, R. Kamaraj. Overview of Biosimilars. Research J. Pharm. and Tech 2018; 11(11): 5152-5158.
16.    Manohar D. Kengar, Kiran K. Patole, Akshay K. Ade, Sumesh M. Kumbhar, Chetan D. Patil, Ashutosh R. Ganjave. Introduction to Pharmacovigilance and Monitoring. Asian J. Pharm. Res. 2019; 9(2): 116-122.
17.    S. S. Shuka, Bina Gidwani, R. Pandey, S. P. Rao, V. Singh, Amber Vyas. Importance of Pharmacovigilance in Indian Pharmaceutical Industry . Asian J. Res. Pharm. Sci. 2(1): Jan.-Mar. 2012; Page 04-08.
18.    Manohar D. Kengar, Ganesh B. Vambhurkar Asha M. Jagtap, Akshata S. Gavade, Manoj kumar M. Nitalikar. A Study on Banned Drugs in India: A Review. Asian J. Res. Pharm. Sci. 2018; 8(4): 258-260.
19.    Nikita R. Nikam, Rohan R. Vakhariya, Dr. C. S. Magdum. Pharmacovigilance: An Overview. Asian J. Res. Pharm. Sci. 2019; 9(2):107-111.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available